Feb 7, 2018 Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Learn More
Jan 29, 2018 Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers Learn More
Jan 22, 2018 Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference Learn More